RxDoctor Payments DataLook up a doctor →

Brian Keogh, MD

Pain Medicine · Greenville, NCNPI 1922324078

Payments from drug & device makers

$23,614in general payments, 2019–2025

Across 504 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Medtronic$5K
  • Saluda Medical Americas, Inc.$2K
  • Biotronik NRO, Inc.$2K
  • Abbott$1K
  • Nevro Corp.$1K
  • plus $5K from 35 others

What the payments were for

  • Speaking & faculty fees$110%
  • Travel & lodging$4,50919%
  • Food & beverage$19,09581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,614 in reported general payments places this provider in the 85th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$200,294
Medicare patients
230
Services billed
5,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Levorphanol Tartrate11$34,230
BelbucaBuprenorphine Hcl26$22,406
Buprenorphine56$13,198
Diclofenac Sodium30$10,229
HorizantGabapentin Enacarbil12$9,833
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen183$8,948
Xtampza ErOxycodone Myristate11$7,696
MovantikNaloxegol Oxalate17$7,282
LinzessLinaclotide11$6,934
Lidocaine22$4,773
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen143$4,332
Fentanyl16$4,253
Oxycodone Hcl210$3,933
Pregabalin167$2,846
Baclofen147$2,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Virtus Pharmaceuticals LLCLevorphanol Tartrate$164$34,23011 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$430$30,10237 claims
Arbor Pharmaceuticals, Inc.Horizant$190$9,83312 claims
Redhill Biopharma Inc.Movantik$21$7,28217 claims
AbbVieLinzess$163$6,93411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →